Lexi
Real TAKHZYRO patient
REIMAGINE YOUR LIFE WITH HAE
TAKHZYRO is a first-of-its-kind medicine used to prevent
attacks of hereditary angioedema (HAE) in people 12 years of
age and older.
See Lexi's
Reimagine Story
Reimagine your life with fewer attacks
Fewer attacks or zero attacks in a study
People taking TAKHZYRO in a clinical study had HAE
attacks less often, and some people in the study had zero
attacks. Want to see the study details? We’d love to share.
In a 26-week clinical trial of 125 people with HAE 12 years of age and older,
TAKHZYRO significantly reduced the number of monthly attacks, compared
with placebo. People taking TAKHZYRO also had fewer moderate or severe
attacks and fewer attacks requiring acute treatment, compared with
placebo. And according to a supportive analysis, there were people taking
TAKHZYRO who had zero attacks during the entire clinical trial.
See Marie's
Reimagine Story
Reimagine your
dosing schedule
TAKHZYRO is a subcutaneous (under-the-skin)
injection you give yourself once every 2 weeks
after being trained by a healthcare provider.
The recommended dose is 300 mg every 2 weeks for people starting on TAKHZYRO. If you have zero attacks for more than 6 months, your doctor may consider prescribing TAKHZYRO 300 mg every 4 weeks.
See what made patients
want to start TAKHZYRO
Ready to ask your doctor about TAKHZYRO?
Curious about what TAKHZYRO could do for you? Ask
your doctor. You can use our discussion guide to help
get the conversation started.
Personalized product support every step of the way
OnePath® helps people who have been prescribed TAKHZYRO per the approved indication get access to their medication.
